Core Insights - Edwards Lifesciences has seen significant institutional investment activity, with various firms acquiring new positions and increasing their holdings in the company [1][6] - Recent analyst ratings show a mix of upgrades and downgrades, with a consensus rating of "Moderate Buy" and a target price of $91.39 [2] - The company's stock performance has been stable, with a current price of $86.74 and a market capitalization of $50.34 billion [3] Institutional Investment - West Family Investments Inc. acquired a new position valued at approximately $208,000 in the second quarter [1] - Skandinaviska Enskilda Banken AB publ increased its holdings by 15.2%, now owning 1,090,051 shares valued at $85.25 million after purchasing an additional 143,603 shares [1] - Norges Bank acquired a new position valued at $580.64 million in the second quarter [1] - Institutional investors and hedge funds collectively own 79.46% of the company's stock [1] Analyst Ratings - Oppenheimer downgraded the stock from "outperform" to "market perform" on October 8th [2] - Raymond James upgraded the stock from "market perform" to "outperform" with a target price of $96.00 on November 3rd [2] - Wells Fargo raised its target price from $84.00 to $88.00, maintaining an "overweight" rating [2] - The consensus rating includes three Strong Buy, fourteen Buy, ten Hold, and one Sell ratings [2] Financial Performance - The company reported earnings per share (EPS) of $0.67 for the last quarter, exceeding the consensus estimate of $0.59 by $0.08 [4] - Revenue for the quarter was $1.55 billion, surpassing analyst estimates of $1.49 billion, and reflecting a year-over-year increase of 14.7% [4] - The company has set FY 2025 EPS guidance at 2.560-2.620 and Q4 2025 guidance at 0.580-0.640 [4] Insider Activity - VP Daniel J. Lippis sold 1,020 shares at an average price of $82.55, resulting in a total transaction of $84,201, representing a 4.43% decrease in ownership [5] - CFO Scott B. Ullem sold 13,000 shares at an average price of $83.08, totaling $1,080,040, which is a 24.58% decrease in ownership [5] - Corporate insiders own 1.29% of the company's stock [5] Company Overview - Edwards Lifesciences specializes in products and technologies for structural heart disease and critical care monitoring [7] - The company offers transcatheter heart valve replacement products and valve repair solutions for various heart conditions [7]